The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells

Leukemia

Volumn 25, Issue 12, 2011, Pages 1891-1899

  Monaghan, K A ^a,b   Khong, T ^a,b   Burns, C J ^c   Spencer, A ^a,b  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c YM BioSciences Australia   (Australia)

Author keywords

CYT387; drug resistance; JAK inhibitors; multiple myeloma; STAT signalling

Indexed keywords

BORTEZOMIB; CYT 387; INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE INHIBITOR; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SOMATOMEDIN C; STAT3 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR CELL LINE;

EID: 83555174315     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.175     Document Type: Article

References (36)

1. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790. (Pubitemid 40570926)
2. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer cell 2005; 7: 387-397. (Pubitemid 40544655)
3. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459-468. (Pubitemid 46193073)
4. Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad SciUSA 2009; 106: 9414-9418.
5. Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene 2000; 19: 5662-5679.
6. French JD, Walters DK, Jelinek DF. Transactivation of gp130 in myeloma cells. J Immunol 2003; 170: 3717-3723. (Pubitemid 36361995)
7. Berger LC, Hawley TS, Lust JA, Goldman SJ, Hawley RG. Tyrosine phosphorylation of JAK-TYK kinases in malignant plasma cell lines growth-stimulated by interleukins 6 and 11. Biochem Biophys Res Commun 1994; 202: 596-605.
8. Gomez-Benito M, Balsas P, Carvajal-Vergara X, Pandiella A, Anel A, Marzo I et al. Mechanism of apoptosis induced by IFNalpha in human myeloma cells: role of Jak1 and Bim and potentiation by rapamycin. Cell Signal 2007; 19: 844-854. (Pubitemid 46275374)
9. Jelinek DF, Ahmann GJ, Greipp PR, Jalal SM, Westendorf JJ, Katzmann JA et al. Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res 1993; 53: 5320-5327. (Pubitemid 23333406)
10. Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 1994; 83: 3654-3663. (Pubitemid 24175556)
11. Cheung WC, Van Ness B. The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro. Leukemia 2001; 15: 264-271. (Pubitemid 32175458)
12. Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103: 3148-3157. (Pubitemid 38451693)
13. Perez LE, Parquet N, Shain K, Nimmanapalli R, Alsina M, Anasetti C et al. Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP. J Immunol 2008; 180: 1545-1555.
14. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73: 517-526. (Pubitemid 19060538)
15. Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J. Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood 1993; 81: 3357-3364. (Pubitemid 23172921)
16. Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010; 115: 5232-5240.
17. Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009; 23: 1441-1445.
18. Burns CJ, Bourke DG, Andrau L, Bu X, Charman SA, Donohue AC et al. Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). Bioorg Med Chem Lett 2009; 19: 5887-5892.
19. Burger R, Le Gouill S, Tai YT, Shringarpure R, Tassone P, Neri P et al. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. Mol Cancer Ther 2009; 8: 26-35.
20. Li J, Favata M, Kelley JA, Caulder E, Thomas B, Wen X et al. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Neoplasia (New York, NY) 2010; 12: 28-38.
21. De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogenactivated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol 2000; 109: 823-828. (Pubitemid 30609763)
22. Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003; 9: 316-326. (Pubitemid 36109748)
23. Scuto A, Krejci P, Popplewell L, Wu J, Wang Y, Kujawski M et al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia 2011; 25: 538-550.
24. Pedranzini L, Dechow T, Berishaj M, Comenzo R, Zhou P, Azare J et al. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res 2006; 66: 9714-9721. (Pubitemid 44623672)
25. Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z et al. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res 2007; 67: 11291-11299. (Pubitemid 350248555)
26. Pardanani A, George G, Lasho T, Hogan WJ, Litzow MR, Begna K et al. A Phase I/II Study of CYT387, An Oral JAK-1/2 Inhibitor, In Myelofibrosis: Significant Response Rates In Anemia, Splenomegaly, and Constitutional Symptoms. Blood; 52nd ASH Annual Meeting and Exposition 6/12/2010; Orlando, Florida, USA, 116. Abstract 460. p. 206.
27. Khong T, Sharkey J, Spencer A. The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Haematologica 2008; 93: 860-869. (Pubitemid 351821722)
28. Monaghan K, Khong T, Smith G, Spencer A. CYT997 Causes apoptosis in human multiple myeloma. Invest New Drugs 2011; 29: 232-238.
29. Zong CS, Chan J, Levy DE, Horvath C, Sadowski HB, Wang LH. Mechanism of STAT3 activation by insulin-like growth factor I receptor. J Biol Chem 2000; 275: 15099-15105. (Pubitemid 30337231)
30. Gual P, Baron V, Lequoy V, Van Obberghen E. Interaction of Janus kinases JAK-1 and JAK-2 with the insulin receptor and the insulinlike growth factor-1 receptor. Endocrinology 1998; 139: 884-893. (Pubitemid 28510102)
31. Chatterjee M, Stuhmer T, Herrmann P, Bommert K, Dorken B, Bargou RC. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 2004; 104: 3712-3721. (Pubitemid 39564449)
32. Kumar S, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia 2005; 19: 1466-1470. (Pubitemid 41136343)
33. Thabard W, Collette M, Mellerin MP, Puthier D, Barille S, Bataille R et al. IL-6 upregulates its own receptor on some human myeloma cell lines. Cytokine 2001; 14: 352-356. (Pubitemid 32730477)
34. Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 1999; 29: 3945-3950.
35. Chatterjee M, Honemann D, Lentzsch S, Bommert K, Sers C, Herrmann P et al. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood 2002; 100: 3311-3318. (Pubitemid 35217082)
36. Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol 2000; 111: 626-634.